ReviewJournal of general internal medicine2009
Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?
Review in Journal of general internal medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.Blood advances · 2018Trial
- Influence of treatment, genetic predisposition, and lifestyle on cardiovascular risk factors among cancer survivors.Journal of the National Cancer Institute · 2026Article
- Emerging Strategies for the Prevention of Chemotherapy-Induced Cardiotoxicity in Paediatric Cancer Patients: Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Persistent variations of blood DNA methylation associated with treatment exposures and risk for cardiometabolic outcomes in long-term survivors of childhood cancer in the St. Jude Lifetime Cohort.Genome medicine · 2021Article
- Current and coming challenges in the management of the survivorship population.Seminars in oncology · 2020Review
- Health Status in Long-Term Survivors of Hepatoblastoma.Cancers · 2019Article
- Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future.Current oncology reports · 2016Review
- Collaborative Research in Childhood Cancer Survivorship: The Current Landscape.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Review
- A prospective study on the attitude of post graduates in general pediatrics toward pediatric oncology subspeciality as a career.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology · 2014Article
- Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.Pediatric blood & cancer · 2013Review
- Disparities in cancer outcomes: lessons learned from children with cancer.Pediatric blood & cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-intensity, risk-based therapeutic strategies for childhood cancer have resulted in long-term survival rates that now approach 80%. However, the growing population of survivors is at a substantial risk for treatment-related complications that can significantly impact quantity and quality of survival. It is increasingly recognized that many of these complications result from complex interactions between therapeutic exposures and genetic susceptibility.
objectiveThis review is designed to increase general clinician awareness of the ongoing efforts by investigators to understand the interactions between therapeutic exposures and genetic susceptibility to therapy-related complications.
resultsMost studies have relied on a biologically plausible candidate gene approach to evaluate genetic susceptibility. This has resulted in the identification of unique genetic polymorphisms that could alter metabolic pathways of therapeutic agents associated with specific adverse events. We highlight some of these findings and discuss their implications for future prevention strategies, as well as their role in elucidating the pathophysiology of these complex diseases.
conclusionResearch exploring the role of genetic susceptibility in the development of therapy-related adverse outcomes is still in its infancy. There is a need for continued efforts to study these outcomes in the context of complex gene-gene and gene-environment interactions unique to cancer survivors. A better understanding of the pathogenesis of these outcomes will help develop effective targeted prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.